Olaparib Cas:763113-22-0
Olaparib is a chemotherapy agent used to treat recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and a history of prior chemotherapy. Olaparib, marketed as an oral tablet, was originally designated as maintenance therapy or monotherapy for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Description:
Olaparib Cas:763113-22-0 is used for maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer with some type of hereditary or acquired (abnormal BRCA gene). It is often used by doctors for maintenance treatment after chemotherapy if your cancer has come back after a previous type of chemotherapy called platinum-based chemotherapy, designed to stop the cancer coming back or growing for as long as possible.
Features：
1. When Olaparib Cas:763113-22-0 prevents PARP from repairing DNA damage, cancer cells die. It can be described as a targeted anti-cancer drug called a cancer growth blocker.
2. It is a targeted therapy and healthcare professionals may use the trade name Lynparza when referring to the generic drug name olaparib.
3. When used to treat ovarian cancer, it may take at least 3 months to start working.
Storage：
Please keep the medicine out of the reach of children.
Please dispose of expired drugs at any time.
Please store the medicine in an airtight container at room temperature, away from heat source, humidity and direct light.
Please put the tablets in the configured container, and don't put them anywhere.
Specification:
Name: Olaparib
| Molecular Formula | C24H23FN4O3 |
|---|---|
| Molecular Weight | 434.46 |
| EINECS | 642-941-5 |
